{"id":59232,"date":"2026-03-11T13:21:12","date_gmt":"2026-03-11T05:21:12","guid":{"rendered":"https:\/\/flcube.com\/?p=59232"},"modified":"2026-03-11T13:21:13","modified_gmt":"2026-03-11T05:21:13","slug":"astellas-xospata-fails-phase-iii-primary-endpoint-in-frontline-aml-flt3-inhibitor-misses-os-benefit-vs-midostaurin","status":"publish","type":"post","link":"https:\/\/flcube.com\/?p=59232","title":{"rendered":"Astellas&#8217; XOSPATA Fails Phase III Primary Endpoint in Frontline AML \u2013 FLT3 Inhibitor Misses OS Benefit vs. Midostaurin"},"content":{"rendered":"\n<p><strong>Astellas Pharma Inc.<\/strong> (<a href=\"https:\/\/www.google.com\/finance\/quote\/4503:TYO\">TYO: 4503<\/a>) and the <strong>HOVON Foundation<\/strong> announced that the <strong>Phase III HOVON 156 \/ AMLSG 28-18 \/ PASHA study<\/strong> of <strong>XOSPATA (gilteritinib)<\/strong> <strong>failed to meet its primary endpoint<\/strong> of <strong>overall survival (OS)<\/strong> in <strong>newly diagnosed FLT3-mutation-positive (FLT3m+) acute myeloid leukemia (AML)<\/strong>. While the study did not demonstrate superior OS versus the <strong>midostaurin-based regimen<\/strong>, gilteritinib showed <strong>comparable survival benefit<\/strong> with <strong>similar safety profiles<\/strong>, preserving its <strong>relapsed\/refractory (R\/R) positioning<\/strong> but <strong>limiting frontline expansion potential<\/strong> for the <strong>$400M+ revenue franchise<\/strong>.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-clinical-trial-results\">Clinical Trial Results<\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Endpoint<\/th><th>XOSPATA (Gilteritinib)<\/th><th>Midostaurin-Based Regimen<\/th><th>Outcome<\/th><\/tr><\/thead><tbody><tr><td><strong>Primary: Overall Survival (OS)<\/strong><\/td><td>Not superior<\/td><td>Standard comparator<\/td><td><strong>Failed to meet primary endpoint<\/strong><\/td><\/tr><tr><td><strong>OS Comparison<\/strong><\/td><td>Comparable benefit<\/td><td>\u2014<\/td><td>Non-inferior but not superior<\/td><\/tr><tr><td><strong>Safety: TEAEs<\/strong><\/td><td>Similar incidence<\/td><td>Midostaurin arm<\/td><td>Manageable toxicity profile<\/td><\/tr><tr><td><strong>Safety: Grade \u22653 AEs<\/strong><\/td><td>Similar rate<\/td><td>Midostaurin arm<\/td><td>No unexpected safety signals<\/td><\/tr><tr><td><strong>Study Population<\/strong><\/td><td>Newly diagnosed FLT3m+ AML, intensive chemo-eligible<\/td><td>\u2014<\/td><td>High-unmet-need population<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<p><strong>Study Design:<\/strong><\/p>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Name:<\/strong> HOVON 156 \/ AMLSG 28-18 \/ PASHA<\/li>\n\n\n\n<li><strong>Phase:<\/strong> III<\/li>\n\n\n\n<li><strong>Comparator:<\/strong> Midostaurin (first-generation FLT3 inhibitor) + intensive chemotherapy<\/li>\n\n\n\n<li><strong>Sponsors:<\/strong> Astellas Pharma + HOVON Foundation (Dutch cooperative group)<\/li>\n<\/ul>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-drug-profile-amp-approved-indications\">Drug Profile &amp; Approved Indications<\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Attribute<\/th><th>Gilteritinib (XOSPATA) Specification<\/th><\/tr><\/thead><tbody><tr><td><strong>Drug Class<\/strong><\/td><td>Second-generation FLT3 tyrosine kinase inhibitor<\/td><\/tr><tr><td><strong>Target Coverage<\/strong><\/td><td>FLT3-ITD (internal tandem duplication) + FLT3-TKD (tyrosine kinase domain) mutations<\/td><\/tr><tr><td><strong>Mechanism<\/strong><\/td><td>Inhibits FLT3 signaling driving leukemic cell proliferation and survival<\/td><\/tr><tr><td><strong>Approved Indications<\/strong><\/td><td><strong>Relapsed or refractory FLT3+ AML<\/strong> (U.S., Japan, China, EU, other regions)<\/td><\/tr><tr><td><strong>Development Partner<\/strong><\/td><td>Kotobuki Pharmaceutical Co., Ltd. (co-development)<\/td><\/tr><tr><td><strong>Global Rights<\/strong><\/td><td>Astellas (exclusive development, commercialization, manufacturing)<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-strategic-implications\">Strategic Implications<\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Factor<\/th><th>Impact<\/th><\/tr><\/thead><tbody><tr><td><strong>Frontline Expansion Blocked<\/strong><\/td><td>XOSPATA remains R\/R-only; midostaurin retains 1L FLT3m+ AML standard-of-care position<\/td><\/tr><tr><td><strong>Revenue Forecast<\/strong><\/td><td>Peak sales estimates reduced; R\/R market saturation limits growth trajectory<\/td><\/tr><tr><td><strong>Competitive Dynamics<\/strong><\/td><td>Quizartinib (Daiichi Sankyo) frontline Phase III ongoing; crenolanib (Arog) development continues<\/td><\/tr><tr><td><strong>Safety Preservation<\/strong><\/td><td>Comparable toxicity to midostaurin supports continued R\/R use; no black box warning risk<\/td><\/tr><tr><td><strong>Label Strategy<\/strong><\/td><td>Potential exploratory endpoints (CR rate, MRD negativity) may support niche positioning<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-competitive-landscape\">Competitive Landscape<\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Competitor<\/th><th>Product<\/th><th>Mechanism<\/th><th>Frontline Status<\/th><th>Post-Trial Implication<\/th><\/tr><\/thead><tbody><tr><td><strong>Novartis<\/strong><\/td><td>Rydapt (midostaurin)<\/td><td>Multi-kinase (FLT3, PKC, etc.)<\/td><td>Approved (1L FLT3m+ AML)<\/td><td>Retains frontline standard; generic pressure 2027+<\/td><\/tr><tr><td><strong>Daiichi Sankyo<\/strong><\/td><td>Vanflyta (quizartinib)<\/td><td>FLT3-ITD selective<\/td><td>Phase III (QuANTUM-First)<\/td><td>Potential frontline entrant if OS benefit demonstrated<\/td><\/tr><tr><td><strong>Arog<\/strong><\/td><td>Crenolanib<\/td><td>Pan-FLT3 (ITD + TKD)<\/td><td>Phase III<\/td><td>Continued development; 2nd-gen positioning<\/td><\/tr><tr><td><strong>Astellas<\/strong><\/td><td><strong>XOSPATA<\/strong><\/td><td><strong>FLT3-ITD + TKD<\/strong><\/td><td><strong>R\/R approved; 1L failed<\/strong><\/td><td><strong>Defensive R\/R franchise; combination studies may continue<\/strong><\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-forward-looking-considerations\">Forward-Looking Considerations<\/h2>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Combination Strategies:<\/strong> XOSPATA + venetoclax + azacitidine (non-intensive) studies ongoing for unfit patients<\/li>\n\n\n\n<li><strong>MRD-Driven Trials:<\/strong> Exploratory endpoints may support adjuvant or maintenance positioning post-remission<\/li>\n\n\n\n<li><strong>Quizartinib Threat:<\/strong> If QuANTUM-First succeeds, XOSPATA R\/R share at risk due to physician familiarity with competitor<\/li>\n\n\n\n<li><strong>Generic Timeline:<\/strong> Midostaurin patent expiry 2027 may open frontline market for cost-effective alternatives<\/li>\n<\/ul>\n\n\n\n<p><strong>Forward\u2011Looking Statements<\/strong><br>This brief contains forward\u2011looking statements regarding XOSPATA&#8217;s commercial trajectory, competitive positioning, and pipeline adjustments following the Phase III failure. Actual results may differ due to competitive dynamics with quizartinib, combination study outcomes, and pricing pressures in the R\/R AML market.<a href=\"https:\/\/flcube.com\/\">-Fineline Info &amp; Tech<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"<p>Astellas Pharma Inc. (TYO: 4503) and the HOVON Foundation announced that the Phase III HOVON&#8230;<\/p>\n","protected":false},"author":1,"featured_media":59233,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"googlesitekit_rrm_CAownpewDA:productID":"","_jetpack_memberships_contains_paid_content":false,"footnotes":"","jetpack_publicize_message":"","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":true,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2}},"categories":[7,11],"tags":[353,16,17,1177],"class_list":["post-59232","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-company","category-drug","tag-astellas-pharma","tag-cancer","tag-clinical-trial-results","tag-tyo-4503"],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v23.6 (Yoast SEO v27.4) - https:\/\/yoast.com\/product\/yoast-seo-premium-wordpress\/ -->\n<title>Astellas&#039; XOSPATA Fails Phase III Primary Endpoint in Frontline AML \u2013 FLT3 Inhibitor Misses OS Benefit vs. Midostaurin - Insight, China&#039;s Pharmaceutical Industry<\/title>\n<meta name=\"description\" content=\"Astellas Pharma Inc. (TYO: 4503) and the HOVON Foundation announced that the Phase III HOVON 156 \/ AMLSG 28-18 \/ PASHA study of XOSPATA (gilteritinib) failed to meet its primary endpoint of overall survival (OS) in newly diagnosed FLT3-mutation-positive (FLT3m+) acute myeloid leukemia (AML). While the study did not demonstrate superior OS versus the midostaurin-based regimen, gilteritinib showed comparable survival benefit with similar safety profiles, preserving its relapsed\/refractory (R\/R) positioning but limiting frontline expansion potential for the $400M+ revenue franchise.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/flcube.com\/?p=59232\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Astellas&#039; XOSPATA Fails Phase III Primary Endpoint in Frontline AML \u2013 FLT3 Inhibitor Misses OS Benefit vs. Midostaurin\" \/>\n<meta property=\"og:description\" content=\"Astellas Pharma Inc. (TYO: 4503) and the HOVON Foundation announced that the Phase III HOVON 156 \/ AMLSG 28-18 \/ PASHA study of XOSPATA (gilteritinib) failed to meet its primary endpoint of overall survival (OS) in newly diagnosed FLT3-mutation-positive (FLT3m+) acute myeloid leukemia (AML). While the study did not demonstrate superior OS versus the midostaurin-based regimen, gilteritinib showed comparable survival benefit with similar safety profiles, preserving its relapsed\/refractory (R\/R) positioning but limiting frontline expansion potential for the $400M+ revenue franchise.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/flcube.com\/?p=59232\" \/>\n<meta property=\"og:site_name\" content=\"Insight, China&#039;s Pharmaceutical Industry\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/profile.php?id=61566606313834\" \/>\n<meta property=\"article:published_time\" content=\"2026-03-11T05:21:12+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2026-03-11T05:21:13+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/flcube.com\/wp-content\/uploads\/2026\/03\/1101.webp\" \/>\n\t<meta property=\"og:image:width\" content=\"1080\" \/>\n\t<meta property=\"og:image:height\" content=\"608\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/png\" \/>\n<meta name=\"author\" content=\"Fineline Cube\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:description\" content=\"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Fineline Cube\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"3 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=59232#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=59232\"},\"author\":{\"name\":\"Fineline Cube\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\"},\"headline\":\"Astellas&#8217; XOSPATA Fails Phase III Primary Endpoint in Frontline AML \u2013 FLT3 Inhibitor Misses OS Benefit vs. Midostaurin\",\"datePublished\":\"2026-03-11T05:21:12+00:00\",\"dateModified\":\"2026-03-11T05:21:13+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=59232\"},\"wordCount\":498,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=59232#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2026\\\/03\\\/1101.webp\",\"keywords\":[\"Astellas Pharma\",\"Cancer\",\"Clinical trial results\",\"TYO: 4503\"],\"articleSection\":[\"Company\",\"Drug\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=59232#respond\"]}],\"copyrightYear\":\"2026\",\"copyrightHolder\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"}},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=59232\",\"url\":\"https:\\\/\\\/flcube.com\\\/?p=59232\",\"name\":\"Astellas' XOSPATA Fails Phase III Primary Endpoint in Frontline AML \u2013 FLT3 Inhibitor Misses OS Benefit vs. Midostaurin - Insight, China&#039;s Pharmaceutical Industry\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=59232#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=59232#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2026\\\/03\\\/1101.webp\",\"datePublished\":\"2026-03-11T05:21:12+00:00\",\"dateModified\":\"2026-03-11T05:21:13+00:00\",\"description\":\"Astellas Pharma Inc. (TYO: 4503) and the HOVON Foundation announced that the Phase III HOVON 156 \\\/ AMLSG 28-18 \\\/ PASHA study of XOSPATA (gilteritinib) failed to meet its primary endpoint of overall survival (OS) in newly diagnosed FLT3-mutation-positive (FLT3m+) acute myeloid leukemia (AML). While the study did not demonstrate superior OS versus the midostaurin-based regimen, gilteritinib showed comparable survival benefit with similar safety profiles, preserving its relapsed\\\/refractory (R\\\/R) positioning but limiting frontline expansion potential for the $400M+ revenue franchise.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=59232#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=59232\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=59232#primaryimage\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2026\\\/03\\\/1101.webp\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2026\\\/03\\\/1101.webp\",\"width\":1080,\"height\":608,\"caption\":\"Astellas' XOSPATA Fails Phase III Primary Endpoint in Frontline AML \u2013 FLT3 Inhibitor Misses OS Benefit vs. Midostaurin\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=59232#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/flcube.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Astellas&#8217; XOSPATA Fails Phase III Primary Endpoint in Frontline AML \u2013 FLT3 Inhibitor Misses OS Benefit vs. Midostaurin\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"name\":\"Insight, China's Pharmaceutical Industry\",\"description\":\"Fineline Insights, Pharma Clarity\",\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/flcube.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\",\"name\":\"Fineline Infomation and Technology\",\"alternateName\":\"Fineline Info & Tech\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"width\":2560,\"height\":1894,\"caption\":\"Fineline Infomation and Technology\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/profile.php?id=61566606313834\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\",\"name\":\"Fineline Cube\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"caption\":\"Fineline Cube\"},\"sameAs\":[\"https:\\\/\\\/flcube.com\"],\"url\":\"https:\\\/\\\/flcube.com\\\/?author=1\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Astellas' XOSPATA Fails Phase III Primary Endpoint in Frontline AML \u2013 FLT3 Inhibitor Misses OS Benefit vs. Midostaurin - Insight, China&#039;s Pharmaceutical Industry","description":"Astellas Pharma Inc. (TYO: 4503) and the HOVON Foundation announced that the Phase III HOVON 156 \/ AMLSG 28-18 \/ PASHA study of XOSPATA (gilteritinib) failed to meet its primary endpoint of overall survival (OS) in newly diagnosed FLT3-mutation-positive (FLT3m+) acute myeloid leukemia (AML). While the study did not demonstrate superior OS versus the midostaurin-based regimen, gilteritinib showed comparable survival benefit with similar safety profiles, preserving its relapsed\/refractory (R\/R) positioning but limiting frontline expansion potential for the $400M+ revenue franchise.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/flcube.com\/?p=59232","og_locale":"en_US","og_type":"article","og_title":"Astellas' XOSPATA Fails Phase III Primary Endpoint in Frontline AML \u2013 FLT3 Inhibitor Misses OS Benefit vs. Midostaurin","og_description":"Astellas Pharma Inc. (TYO: 4503) and the HOVON Foundation announced that the Phase III HOVON 156 \/ AMLSG 28-18 \/ PASHA study of XOSPATA (gilteritinib) failed to meet its primary endpoint of overall survival (OS) in newly diagnosed FLT3-mutation-positive (FLT3m+) acute myeloid leukemia (AML). While the study did not demonstrate superior OS versus the midostaurin-based regimen, gilteritinib showed comparable survival benefit with similar safety profiles, preserving its relapsed\/refractory (R\/R) positioning but limiting frontline expansion potential for the $400M+ revenue franchise.","og_url":"https:\/\/flcube.com\/?p=59232","og_site_name":"Insight, China&#039;s Pharmaceutical Industry","article_publisher":"https:\/\/www.facebook.com\/profile.php?id=61566606313834","article_published_time":"2026-03-11T05:21:12+00:00","article_modified_time":"2026-03-11T05:21:13+00:00","og_image":[{"width":1080,"height":608,"url":"https:\/\/flcube.com\/wp-content\/uploads\/2026\/03\/1101.webp","type":"image\/png"}],"author":"Fineline Cube","twitter_card":"summary_large_image","twitter_description":"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM","twitter_misc":{"Written by":"Fineline Cube","Est. reading time":"3 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/flcube.com\/?p=59232#article","isPartOf":{"@id":"https:\/\/flcube.com\/?p=59232"},"author":{"name":"Fineline Cube","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a"},"headline":"Astellas&#8217; XOSPATA Fails Phase III Primary Endpoint in Frontline AML \u2013 FLT3 Inhibitor Misses OS Benefit vs. Midostaurin","datePublished":"2026-03-11T05:21:12+00:00","dateModified":"2026-03-11T05:21:13+00:00","mainEntityOfPage":{"@id":"https:\/\/flcube.com\/?p=59232"},"wordCount":498,"commentCount":0,"publisher":{"@id":"https:\/\/flcube.com\/#organization"},"image":{"@id":"https:\/\/flcube.com\/?p=59232#primaryimage"},"thumbnailUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2026\/03\/1101.webp","keywords":["Astellas Pharma","Cancer","Clinical trial results","TYO: 4503"],"articleSection":["Company","Drug"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/flcube.com\/?p=59232#respond"]}],"copyrightYear":"2026","copyrightHolder":{"@id":"https:\/\/flcube.com\/#organization"}},{"@type":"WebPage","@id":"https:\/\/flcube.com\/?p=59232","url":"https:\/\/flcube.com\/?p=59232","name":"Astellas' XOSPATA Fails Phase III Primary Endpoint in Frontline AML \u2013 FLT3 Inhibitor Misses OS Benefit vs. Midostaurin - Insight, China&#039;s Pharmaceutical Industry","isPartOf":{"@id":"https:\/\/flcube.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/flcube.com\/?p=59232#primaryimage"},"image":{"@id":"https:\/\/flcube.com\/?p=59232#primaryimage"},"thumbnailUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2026\/03\/1101.webp","datePublished":"2026-03-11T05:21:12+00:00","dateModified":"2026-03-11T05:21:13+00:00","description":"Astellas Pharma Inc. (TYO: 4503) and the HOVON Foundation announced that the Phase III HOVON 156 \/ AMLSG 28-18 \/ PASHA study of XOSPATA (gilteritinib) failed to meet its primary endpoint of overall survival (OS) in newly diagnosed FLT3-mutation-positive (FLT3m+) acute myeloid leukemia (AML). While the study did not demonstrate superior OS versus the midostaurin-based regimen, gilteritinib showed comparable survival benefit with similar safety profiles, preserving its relapsed\/refractory (R\/R) positioning but limiting frontline expansion potential for the $400M+ revenue franchise.","breadcrumb":{"@id":"https:\/\/flcube.com\/?p=59232#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/flcube.com\/?p=59232"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/?p=59232#primaryimage","url":"https:\/\/flcube.com\/wp-content\/uploads\/2026\/03\/1101.webp","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2026\/03\/1101.webp","width":1080,"height":608,"caption":"Astellas' XOSPATA Fails Phase III Primary Endpoint in Frontline AML \u2013 FLT3 Inhibitor Misses OS Benefit vs. Midostaurin"},{"@type":"BreadcrumbList","@id":"https:\/\/flcube.com\/?p=59232#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/flcube.com\/"},{"@type":"ListItem","position":2,"name":"Astellas&#8217; XOSPATA Fails Phase III Primary Endpoint in Frontline AML \u2013 FLT3 Inhibitor Misses OS Benefit vs. Midostaurin"}]},{"@type":"WebSite","@id":"https:\/\/flcube.com\/#website","url":"https:\/\/flcube.com\/","name":"Insight, China's Pharmaceutical Industry","description":"Fineline Insights, Pharma Clarity","publisher":{"@id":"https:\/\/flcube.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/flcube.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/flcube.com\/#organization","name":"Fineline Infomation and Technology","alternateName":"Fineline Info & Tech","url":"https:\/\/flcube.com\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/","url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","width":2560,"height":1894,"caption":"Fineline Infomation and Technology"},"image":{"@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/profile.php?id=61566606313834"]},{"@type":"Person","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a","name":"Fineline Cube","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","caption":"Fineline Cube"},"sameAs":["https:\/\/flcube.com"],"url":"https:\/\/flcube.com\/?author=1"}]}},"jetpack_publicize_connections":[],"jetpack_featured_media_url":"https:\/\/flcube.com\/wp-content\/uploads\/2026\/03\/1101.webp","jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/59232","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=59232"}],"version-history":[{"count":1,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/59232\/revisions"}],"predecessor-version":[{"id":59234,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/59232\/revisions\/59234"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/media\/59233"}],"wp:attachment":[{"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=59232"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=59232"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=59232"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}